{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:42:12Z","timestamp":1793403732481,"version":"4.5.0"},"reference-count":83,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2014-7146"],"award-info":[{"award-number":["2014-7146"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2014-6696"],"award-info":[{"award-number":["2014-6696"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["TILC, 694502"],"award-info":[{"award-number":["TILC, 694502"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["prioneer ANR-17-RHUS-0007"],"award-info":[{"award-number":["prioneer ANR-17-RHUS-0007"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["Equipe labellisee"],"award-info":[{"award-number":["Equipe labellisee"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0761-3","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T10:59:24Z","timestamp":1571309964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":273,"title":["Monalizumab: inhibiting the novel immune checkpoint NKG2A"],"prefix":"10.1136","volume":"7","author":[{"given":"Thorbald","family":"van Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Fu","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Narni-Mancinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd H.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"761_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for Cancer. Annu Rev Immunol. 2016;34:539\u201373.","journal-title":"Annu Rev Immunol"},{"issue":"7637","key":"761_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"12","key":"761_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"T Okazaki","year":"2013","unstructured":"Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12):1212\u20138.","journal-title":"Nat Immunol"},{"issue":"7","key":"761_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813\u201324.","journal-title":"Int Immunol"},{"issue":"6230","key":"761_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374.","journal-title":"Science"},{"issue":"2","key":"761_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205\u201314.","journal-title":"Cell"},{"issue":"7528","key":"761_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577\u201381.","journal-title":"Nature"},{"issue":"7528","key":"761_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"6375","key":"761_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582\u20137.","journal-title":"Science"},{"issue":"4","key":"761_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to Cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"key":"761_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","volume":"117","author":"GM Konjevic","year":"2019","unstructured":"Konjevic GM, Vuletic AM, Mirjacic Martinovic KM, Larsen AK, Jurisic VB. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. 2019;117:30\u201340.","journal-title":"Cytokine"},{"issue":"3","key":"761_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","volume":"10","author":"D Wang","year":"2010","unstructured":"Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"761_CR13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis e Sousa C. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting Cancer immune control. Cell. 2018;172(5):1022\u201337 e1014.","journal-title":"Cell"},{"issue":"12","key":"761_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.110","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer (vol 17, pg 709, 2017). Nat Rev Cancer. 2017;17(12):765.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"761_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540\u201354 e1512.","journal-title":"Cell"},{"key":"761_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44\u201351.","journal-title":"Curr Opin Immunol"},{"issue":"45","key":"761_CR17","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/onc.2008.273","volume":"27","author":"M Campoli","year":"2008","unstructured":"Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27(45):5869\u201385.","journal-title":"Oncogene"},{"key":"761_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0065-230X(01)83005-0","volume":"83","author":"F Garrido","year":"2001","unstructured":"Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83:117\u201358.","journal-title":"Adv Cancer Res"},{"issue":"2","key":"761_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0167-5699(96)10075-X","volume":"18","author":"F Garrido","year":"1997","unstructured":"Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997;18(2):89\u201395.","journal-title":"Immunol Today"},{"issue":"4","key":"761_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1357-4310(99)01451-3","volume":"5","author":"DJ Hicklin","year":"1999","unstructured":"Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today. 1999;5(4):178\u201386.","journal-title":"Mol Med Today"},{"issue":"3a","key":"761_CR21","first-page":"1525","volume":"24","author":"A Hiraki","year":"2004","unstructured":"Hiraki A, Fujii N, Murakami T, Kiura K, Aoe K, Yamane H, Masuda K, Maeda T, Sugi K, Darzynkiewicz Z, et al. High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines. Anticancer Res. 2004;24(3a):1525\u20138.","journal-title":"Anticancer Res"},{"key":"761_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","volume":"74","author":"FM Marincola","year":"2000","unstructured":"Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181\u2013273.","journal-title":"Adv Immunol"},{"issue":"6","key":"761_CR23","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al. Allele-specific HLA loss and immune escape in lung Cancer evolution. Cell. 2017;171(6):1259\u201371 e1211.","journal-title":"Cell"},{"issue":"2","key":"761_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-007-0362-8","volume":"57","author":"AM Mehta","year":"2008","unstructured":"Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008;57(2):197\u2013206.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"761_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/scbi.2001.0404","volume":"12","author":"B Seliger","year":"2002","unstructured":"Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12(1):3\u201313.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"761_CR26","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","volume":"175","author":"N Montfoort van","year":"2018","unstructured":"van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Andre P, et al. NKG2A blockade potentiates CD8 T cell immunity induced by Cancer vaccines. Cell. 2018;175(7):1744\u201355 e1715.","journal-title":"Cell"},{"issue":"7","key":"761_CR27","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Blery M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731\u201343 e1713.","journal-title":"Cell"},{"key":"761_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature. 1998;391:795\u20139.","journal-title":"Nature"},{"issue":"1","key":"761_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O","volume":"28","author":"E Drean Le","year":"1998","unstructured":"Le Drean E, Vely F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol. 1998;28(1):264\u201376.","journal-title":"Eur J Immunol"},{"key":"761_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0092-8674(94)90550-9","volume":"79","author":"CJ Aldrich","year":"1994","unstructured":"Aldrich CJ, DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. Identification of a tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell. 1994;79:649\u201358.","journal-title":"Cell"},{"issue":"12\u201313","key":"761_CR31","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.micinf.2010.07.011","volume":"12","author":"T Hall van","year":"2010","unstructured":"van Hall T, Oliveira CC, Joosten SA, Ottenhoff TH. The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect. 2010;12(12\u201313):910\u20138.","journal-title":"Microbes Infect"},{"issue":"10","key":"761_CR32","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.4049\/jimmunol.160.10.4951","volume":"160","author":"N Lee","year":"1998","unstructured":"Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol. 1998;160(10):4951\u201360.","journal-title":"J Immunol"},{"issue":"6","key":"761_CR33","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.4049\/jimmunol.1601679","volume":"198","author":"V Ramsuran","year":"2017","unstructured":"Ramsuran V, Hernandez-Sanchez PG, O'HUigin C, Sharma G, Spence N, Augusto DG, Gao X, Garcia-Sepulveda CA, Kaur G, Mehra NK, et al. Sequence and phylogenetic analysis of the Untranslated promoter regions for HLA class I genes. J Immunol. 2017;198(6):2320\u20139.","journal-title":"J Immunol"},{"issue":"15","key":"761_CR34","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1093\/hmg\/ddv158","volume":"24","author":"V Ramsuran","year":"2015","unstructured":"Ramsuran V, Kulkarni S, O'Huigin C, Yuki Y, Augusto DG, Gao X, Carrington M. Epigenetic regulation of differential HLA-A allelic expression levels. Hum Mol Genet. 2015;24(15):4268\u201375.","journal-title":"Hum Mol Genet"},{"issue":"6371","key":"761_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aam8825","volume":"359","author":"V Ramsuran","year":"2018","unstructured":"Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, Gao X, Walker-Sperling V, Del Prete GQ, Schneider DK, et al. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science. 2018;359(6371):86\u201390.","journal-title":"Science"},{"issue":"4","key":"761_CR36","first-page":"237","volume":"2","author":"EJ Yunis","year":"2007","unstructured":"Yunis EJ, Romero V, Diaz-Giffero F, Zuniga J, Koka P. Natural killer cell receptor NKG2A\/HLA-E interaction dependent differential Thymopoiesis of hematopoietic progenitor cells influences the outcome of HIV infection. J Stem Cells. 2007;2(4):237\u201348.","journal-title":"J Stem Cells"},{"key":"761_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1097-2765(00)80053-2","volume":"1","author":"CA O'Callaghan","year":"1998","unstructured":"O'Callaghan CA, Tormo J, Willcox BE, Braud VM, Jakobsen BK, Stuart DI, McMichael AJ, Bell JI, Jones EY. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol Cell. 1998;1:531\u201341.","journal-title":"Mol Cell"},{"issue":"1","key":"761_CR38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4049\/jimmunol.1102379","volume":"188","author":"L Zeng","year":"2012","unstructured":"Zeng L, Sullivan LC, Vivian JP, Walpole NG, Harpur CM, Rossjohn J, Clements CS, Brooks AG. A structural basis for antigen presentation by the MHC class Ib molecule, Qa-1b. J Immunol. 2012;188(1):302\u201310.","journal-title":"J Immunol"},{"issue":"26","key":"761_CR39","doi-asserted-by":"publisher","first-page":"10656","DOI":"10.1073\/pnas.1100354108","volume":"108","author":"M Gooden","year":"2011","unstructured":"Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van Hall T. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8 T lymphocytes. Proc Natl Acad Sci U S A. 2011;108(26):10656\u201361.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"761_CR40","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.18632\/oncotarget.6506","volume":"7","author":"M Talebian Yazdi","year":"2016","unstructured":"Talebian Yazdi M, van Riet S, van Schadewijk A, Fiocco M, van Hall T, Taube C, Hiemstra PS, van der Burg SH. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget. 2016;7(3):3477\u201388.","journal-title":"Oncotarget"},{"issue":"4","key":"761_CR41","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/ijc.28713","volume":"135","author":"EM Esch van","year":"2014","unstructured":"van Esch EM, Tummers B, Baartmans V, Osse EM, Ter Haar N, Trietsch MD, Hellebrekers BW, Holleboom CA, Nagel HT, Tan LT, et al. Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy. Int J Cancer. 2014;135(4):830\u201342.","journal-title":"Int J Cancer"},{"issue":"33","key":"761_CR42","doi-asserted-by":"publisher","first-page":"20035","DOI":"10.1074\/jbc.271.33.20035","volume":"271","author":"KS Gustafson","year":"1996","unstructured":"Gustafson KS, Ginder GD. Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1alpha to a distinct interferon-gamma-responsive element. J Biol Chem. 1996;271(33):20035\u201346.","journal-title":"J Biol Chem"},{"issue":"10","key":"761_CR43","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1172\/JCI0215564","volume":"110","author":"KJ Malmberg","year":"2002","unstructured":"Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Soderstrom K, Levitskaya J, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94\/NKG2A-dependent mechanism. J Clin Invest. 2002;110(10):1515\u201323.","journal-title":"J Clin Invest"},{"key":"761_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/ni757","volume":"3","author":"JM Moser","year":"2002","unstructured":"Moser JM, Gibbs J, Jensen PE, Lukacher AE. CD94-NKG2A receptors regulate antiviral CD8+ T cell responses. Nature immunol. 2002;3:189\u201395.","journal-title":"Nature immunol"},{"issue":"6","key":"761_CR45","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.immuni.2015.11.005","volume":"43","author":"AS Rapaport","year":"2015","unstructured":"Rapaport AS, Schriewer J, Gilfillan S, Hembrador E, Crump R, Plougastel BF, Wang Y, Le Friec G, Gao J, Cella M, et al. The inhibitory receptor NKG2A sustains virus-specific CD8(+) T cells in response to a lethal poxvirus infection. Immunity. 2015;43(6):1112\u201324.","journal-title":"Immunity"},{"issue":"7","key":"761_CR46","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-04-2108","volume":"65","author":"BC Sheu","year":"2005","unstructured":"Sheu BC, Chiou SH, Lin HH, Chow SN, Huang SC, Ho HN, Hsu SM. Up-regulation of inhibitory natural killer receptors CD94\/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res. 2005;65(7):2921\u20139.","journal-title":"Cancer Res"},{"key":"761_CR47","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1038\/ncomms6108","volume":"5","author":"C Viant","year":"2014","unstructured":"Viant C, Fenis A, Chicanne G, Payrastre B, Ugolini S, Vivier E. SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. Nat Commun. 2014;5:5108.","journal-title":"Nat Commun"},{"issue":"5","key":"761_CR48","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI123955","volume":"129","author":"Takahiro Kamiya","year":"2019","unstructured":"Kamiya T, Seow SV, Wong D, Robinson M, Campana D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest. 2019;129(5):2094\u2013106.","journal-title":"Journal of Clinical Investigation"},{"key":"761_CR49","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/ni1063","volume":"5","author":"D Hu","year":"2004","unstructured":"Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol. 2004;5:516\u201323.","journal-title":"Nat Immunol"},{"issue":"5","key":"761_CR50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41423-019-0224-2","volume":"16","author":"Guillaume Habif","year":"2019","unstructured":"Habif G, Crinier A, Andre P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019;16(5):415\u201322.","journal-title":"Cellular & Molecular Immunology"},{"issue":"9","key":"761_CR51","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1172\/JCI45816","volume":"121","author":"E Mamessier","year":"2011","unstructured":"Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609\u201322.","journal-title":"J Clin Invest"},{"issue":"1","key":"761_CR52","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1052213","volume":"5","author":"E Andersson","year":"2016","unstructured":"Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV. Non-classical HLA-class I expression in serous ovarian carcinoma: correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. Oncoimmunology. 2016;5(1):e1052213.","journal-title":"Oncoimmunology"},{"issue":"12","key":"761_CR53","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.4049\/jimmunol.1002629","volume":"185","author":"EM Kruijf de","year":"2010","unstructured":"de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, Liefers GJ, van den Elsen PJ, van de Velde CJ, Kuppen PJ. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol. 2010;185(12):7452\u20139.","journal-title":"J Immunol"},{"issue":"10","key":"761_CR54","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.4049\/jimmunol.168.10.4864","volume":"168","author":"L Derre","year":"2002","unstructured":"Derre L, Corvaisier M, Pandolfino MC, Diez E, Jotereau F, Gervois N. Expression of CD94\/NKG2-a on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. J Immunol. 2002;168(10):4864\u201370.","journal-title":"J Immunol"},{"issue":"3","key":"761_CR55","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/eji.200425735","volume":"35","author":"A Gunturi","year":"2005","unstructured":"Gunturi A, Berg RE, Crossley E, Murray S, Forman J. The role of TCR stimulation and TGF-beta in controlling the expression of CD94\/NKG2A receptors on CD8 T cells. Eur J Immunol. 2005;35(3):766\u201375.","journal-title":"Eur J Immunol"},{"key":"761_CR56","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","volume":"37","author":"D Masopust","year":"2019","unstructured":"Masopust D, Soerens AG. Tissue-resident T cells and other resident leukocytes. Annu Rev Immunol. 2019;37:521\u201346.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"761_CR57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/ni.3589","volume":"17","author":"P Hombrink","year":"2016","unstructured":"Hombrink P, Helbig C, Backer RA, Piet B, Oja AE, Stark R, Brasser G, Jongejan A, Jonkers RE, Nota B, et al. Programs for the persistence, vigilance and control of human CD8(+) lung-resident memory T cells. Nat Immunol. 2016;17(12):1467\u201378.","journal-title":"Nat Immunol"},{"issue":"6","key":"761_CR58","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI44675","volume":"121","author":"B Piet","year":"2011","unstructured":"Piet B, de Bree GJ, Smids-Dierdorp BS, van der Loos CM, Remmerswaal EB, von der Thusen JH, van Haarst JM, Eerenberg JP, ten Brinke A, van der Bij W, et al. CD8(+) T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest. 2011;121(6):2254\u201363.","journal-title":"J Clin Invest"},{"issue":"7","key":"761_CR59","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","volume":"24","author":"P Savas","year":"2018","unstructured":"Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24(7):986\u201393.","journal-title":"Nat Med"},{"key":"761_CR60","unstructured":"Hamid MA, Wang R, al e:Enriched HLA-E and CD94\/NKG2a interaction attenuates tumor-infiltrating CD8 T lymphocyte responses. CIR 2019, in press."},{"issue":"1","key":"761_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4049\/jimmunol.180.1.25","volume":"180","author":"J Zhou","year":"2008","unstructured":"Zhou J, Matsuoka M, Cantor H, Homer R, Enelow RI. Cutting edge: engagement of NKG2A on CD8+ effector T cells limits immunopathology in influenza pneumonia. J Immunol. 2008;180(1):25\u20139.","journal-title":"J Immunol"},{"issue":"8","key":"761_CR62","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24(8):1178\u201391.","journal-title":"Nat Med"},{"issue":"501","key":"761_CR63","doi-asserted-by":"publisher","first-page":"eaav7816","DOI":"10.1126\/scitranslmed.aav7816","volume":"11","author":"Rachael M. Zemek","year":"2019","unstructured":"Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A et al. Sensitization to immune checkpoint blockade through activation of a STAT1\/NK axis in the tumor microenvironment. Sci Transl Med. 2019;11(501):eaav7816.","journal-title":"Science Translational Medicine"},{"issue":"7","key":"761_CR64","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","volume":"177","author":"L Gauthier","year":"2019","unstructured":"Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, Trichard S, Cesari C, Sapet M, Bosco F, et al. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity. Cell. 2019;177(7):1701.","journal-title":"Cell"},{"issue":"9","key":"761_CR65","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025\u201336.","journal-title":"Nat Immunol"},{"issue":"1","key":"761_CR66","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1038\/s41467-019-10335-5","volume":"10","author":"BI Pereira","year":"2019","unstructured":"Pereira BI, Devine OP, Vukmanovic-Stejic M, Chambers ES, Subramanian P, Patel N, Virasami A, Sebire NJ, Kinsler V, Valdovinos A, et al. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8(+) T cell inhibition. Nat Commun. 2019;10(1):2387.","journal-title":"Nat Commun"},{"issue":"6421","key":"761_CR67","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1126\/science.aas9090","volume":"362","author":"M Ruscetti","year":"2018","unstructured":"Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362(6421):1416\u201322.","journal-title":"Science"},{"issue":"4","key":"761_CR68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc.2016.16","volume":"16","author":"SH Burg van der","year":"2016","unstructured":"van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16(4):219\u201333.","journal-title":"Nat Rev Cancer"},{"issue":"7738","key":"761_CR69","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240\u20135.","journal-title":"Nature"},{"issue":"1","key":"761_CR70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related Cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(1):67\u201373.","journal-title":"JAMA Oncol"},{"issue":"7662","key":"761_CR71","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321.","journal-title":"Nature"},{"issue":"3","key":"761_CR72","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cell.2017.11.037","volume":"172","author":"AD Barrow","year":"2018","unstructured":"Barrow AD, Edeling MA, Trifonov V, Luo J, Goyal P, Bohl B, Bando JK, Kim AH, Walker J, Andahazy M, et al. Natural killer cells control tumor growth by sensing a growth factor. Cell. 2018;172(3):534\u201348 e519.","journal-title":"Cell"},{"issue":"1","key":"761_CR73","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2017.12.007","volume":"48","author":"A Glasner","year":"2018","unstructured":"Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, et al. NKp46 receptor-mediated interferon-gamma production by natural killer cells increases Fibronectin 1 to Alter tumor architecture and control metastasis. Immunity. 2018;48(1):107\u201319 e104.","journal-title":"Immunity"},{"issue":"7","key":"761_CR74","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1172\/JCI92958","volume":"127","author":"EM Putz","year":"2017","unstructured":"Putz EM, Mayfosh AJ, Kos K, Barkauskas DS, Nakamura K, Town L, Goodall KJ, Yee DY, Poon IK, Baschuk N, et al. NK cell heparanase controls tumor invasion and immune surveillance. J Clin Invest. 2017;127(7):2777\u201388.","journal-title":"J Clin Invest"},{"issue":"2","key":"761_CR75","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.it.2018.12.003","volume":"40","author":"F Souza-Fonseca-Guimaraes","year":"2019","unstructured":"Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in Cancer immunotherapy. Trends Immunol. 2019;40(2):142\u201358.","journal-title":"Trends Immunol"},{"key":"761_CR76","doi-asserted-by":"crossref","unstructured":"Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in solid tumors and hematological malignancies. Nat Rev Immunol. 2018; in press.","DOI":"10.1038\/s41577-018-0077-4"},{"issue":"7749","key":"761_CR77","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanic M, Reading JL, Joshi K, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479\u201385.","journal-title":"Nature"},{"issue":"2","key":"761_CR78","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","volume":"25","author":"N Anfossi","year":"2006","unstructured":"Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25(2):331\u201342.","journal-title":"Immunity"},{"issue":"3","key":"761_CR79","doi-asserted-by":"publisher","first-page":"eaag1672","DOI":"10.1126\/sciimmunol.aag1672","volume":"1","author":"Amir Horowitz","year":"2016","unstructured":"Horowitz A, Djaoud Z, Nemat-Gorgani N, Blokhuis J, Hilton HG, Beziat V, Malmberg KJ, Norman PJ, Guethlein LA, Parham P. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci Immunol. 2016;1(3):eaag1672.","journal-title":"Science Immunology"},{"issue":"13","key":"761_CR80","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood-2018-09-874990","volume":"133","author":"A Hallner","year":"2019","unstructured":"Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, Martner A, Hellstrand K, Thoren FB. The HLA-B \u221221 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood. 2019;133(13):1479\u201388.","journal-title":"Blood"},{"issue":"11","key":"761_CR81","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00251-002-0526-9","volume":"54","author":"R Marin","year":"2003","unstructured":"Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F. Analysis of HLA-E expression in human tumors. Immunogenetics. 2003;54(11):767\u201375.","journal-title":"Immunogenetics"},{"issue":"14","key":"761_CR82","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1182\/blood-2012-10-459545","volume":"121","author":"V Beziat","year":"2013","unstructured":"Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT, Retiere C, Sverremark-Ekstrom E, Traherne J, Ljungman P, et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood. 2013;121(14):2678\u201388.","journal-title":"Blood"},{"key":"761_CR83","doi-asserted-by":"crossref","unstructured":"Zhang C, Wang XM, Li SR, Twelkmeyer T, Wang WH, Zhang SY, Wang SF, Chen JZ, Jin X, Wu YZ, et al. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun. 2019;10(1):1507.","DOI":"10.1038\/s41467-019-09212-y"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0761-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0761-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0761-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T16:07:08Z","timestamp":1695312428000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0761-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0761-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.A., R.Z. and E. V are employees of Innate-Pharma. The other authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}